The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There is no way on this earth they would have ordered the production plant to make the fiesta model. They know it works.
F1 Mask on its way and 100% guaranteed the NHS will take the lot. It was govt funded !
Themis,
I read it that the machine wont be commissioned till December.
As presumable the company has done the math, it looks like if the new development masks (The Ferrari) do not come up to standard, the conventional mask (The Fiesta) will still make a profit.
Obviously a Ferrari is proffered to a Fiesta, but if they can sell lots of Fiestas for a reasonable profit, its a win win either way.
Looking back to the all Share Purchase Agreement of P2F, Braveheart had to have great belief in what was already the holdings and direction that RMS were taking to accept such a none monetary deal, Braveheart obviously have more insider knowledge that us PI's via the due diligence), so looking deeper RMS's other avenues of revenue must have looked very positive.
the highlight in your post 'In the event that these tests do not provide a satisfactory outcome' in my opinion is a bit of a red herring, I would bet a pound to a penny that the outcome will be satifactory, I think that they have taken a responsible position by including that in the rns but probably already have a good idea about the outcome, I suppose we will have to wait a week or 2 or 3 to know, all positives for me.
Having been in here for a long time I am hopeful that something does come up soon, however when you read today's RNS "In the event that these tests do not provide a satisfactory outcome, the production line will be used to produce conventional surgical type masks, which P2F believe could still be produced on a profitable basis." It does make me wonder. It's a bit like saying I have a Ferrari to sell but if I don't manage to get a Ferrari I'll just sell you a fiesta instead.
Is the production line going to produce conventional masks now rather than sit idle?
The demand is there now, I’d like to think it isn’t going to sit and gather dust as we head into winter.
18 September 2020
Braveheart Investment Group plc
("Braveheart" or the "Group")
Update on the Pharm2Farm anti-viral mask project
Braveheart Investment Group (AIM: BRH), is pleased to announce that Pharm 2 Farm Limited ("P2F") has placed an order for an automated face mask production line which is expected to be delivered in November 2020 and commissioned by the end of December 2020.
The face mask production line, which is manufactured in Europe, has the capacity to produce up to five million standard or anti-viral face masks per month.
Conventional surgical type masks typically comprise of three layers, with the inner layer acting as a physical barrier to viruses and bacteria. However, they are only recommended for up to two hours of continual use as this layer can become moist and fail, thereby allowing the virus to penetrate though. P2F has developed a second defensive layer that incorporates its own nanotechnology, which is engineered to kill viruses and bacteria. Combining this new active layer with the physical barrier layer, to produce four layer (ply) masks, is expected to improve user safety over a prolonged use. This new material is currently undergoing testing, specifically, with respect to the time taken to kill viruses, including COVID-19. These tests are, being undertaken at the University of Nottingham and results are expected by the beginning of October. Following a satisfactory outcome of the tests undertaken at the University of Nottingham, it is envisaged that manufacture of the anti-viral face masks will commence in the first quarter of 2021. In the event that these tests do not provide a satisfactory outcome, the production line will be used to produce conventional surgical type masks, which P2F believe could still be produced on a profitable basis.